Welcome!

News Feed Item

China Human Vaccine Industry (Hepatitis B, Influenza, Rabies & Pneumonia) 2017 Forecasts

DALLAS, August 31, 2014 /PRNewswire/ --

LifeScienceIndustryResearch.com adds "China Human Vaccine Industry Report, 2014-2017" that says vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China's human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run.

Affected by China's economic level, national vaccine prevention policies and people's awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine "IPV" for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine "OPV" for the third and fourth vaccinations.

Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively.

Order a copy of this report at http://www.lifescienceindustryresearch.com/purchase?rname=21800 .

The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year.

As China's vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015.

Comprehensive Table of Contents and more for the report "China Human Vaccine Industry Report, 2014-2017" is available at http://www.lifescienceindustryresearch.com/china-human-vaccine-industry-report-2014-2017.html#tabs-2 .

The report covers: Operating environment, status quo and sales channels of China human vaccine industry; Market supply & demand, competition patterns, import & export and development prediction of China human vaccine industry; Market supply & demand, competition patterns and market prices of 10 kinds of vaccine products including hepatitis B vaccine, influenza vaccine, rabies vaccine and pneumonia vaccine in China; Operation, vaccine business and development prospects of 11 Chinese human vaccine enterprises.

Few Points from Table of Contents of China Human Vaccine Industry Report, 2014-2017 : 

5. Major Vaccine Manufacturers in China

5.1 China National Biotec Group

5.2 Hualan Biological Engineering Inc.

5.3 Chongqing Zhifei Biological Products Co., Ltd

5.4 Walvax Biotechnology Co., Ltd

5.5 Sinovac Biotech Ltd.

5.6 Liaoning Chengda Co., Ltd.

5.7 Changchun BCHT Biotechnology Co. Ltd.

5.8 Changchun Changsheng Life Sciences Limited

5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd

5.10 Shenzhen Kangtai Biological Products Co. Ltd

5.11 Dalian Hissen Bio-Pharm Co., Ltd

List of Figures

Classification of Vaccines

Vaccine Industry Chain

EPI Human Vaccine Varieties in China, 2013

Global Human Vaccine Market Scale, 2008-2013

Sales Value of the Global Top 5 Human Vaccine Manufacturers, 2008-2013

Top 10 Best-selling Vaccines Worldwide, 2013

Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005- 2014

Policies in Vaccine Industry in China

Operating Revenue and Total Profit of Biological & Biochemical Product Industry in China, 2007- 2014

China's Human Vaccine Market Scale, 2007-2013

Major Human Vaccine Varieties and Producers in China

Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2013

The Release and Percentage (by Volume) of EPI and Extra EPI Vaccines in China, 2007-2013

China's EPI Human Vaccine Market Shares by Release, 2008-2013

China's Extra EPI Human Vaccine Market Shares by Release, 2008-2013

Vaccine Business Revenue of Key Vaccine Enterprises in China, 2011-2013

Development of Some New Vaccine in China by the end of Aug., 2014

Some Events Related to Vaccine Business of Foreign Enterprises in China, 2011-2013

Vaccine Distribution Channel in China

Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2013

Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2013

Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2013

Explore more reports on the pharmaceuticals industry at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .

About Us: 

Life Science Industry Research is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, biotechnology, diagnostics, healthcare as well as medical devices and pharmaceuticals. We provide 24/7 online and offline support to our customers.

Priyank Tiwari / Ritesh Tiwari, +1-888-391-5441

SOURCE Life Science Industry Research

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Codigm is based on the cloud and we are here to explore marketing opportunities in America. Our mission is to make an ecosystem of the SW environment that anyone can understand, learn, teach, and develop the SW on the cloud," explained Sung Tae Ryu, CEO of Codigm, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
"CA has been doing a lot of things in the area of DevOps. Now we have a complete set of tool sets in order to enable customers to go all the way from planning to development to testing down to release into the operations," explained Aruna Ravichandran, Vice President of Global Marketing and Strategy at CA Technologies, in this SYS-CON.tv interview at DevOps Summit at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"There's plenty of bandwidth out there but it's never in the right place. So what Cedexis does is uses data to work out the best pathways to get data from the origin to the person who wants to get it," explained Simon Jones, Evangelist and Head of Marketing at Cedexis, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We're developing a software that is based on the cloud environment and we are providing those services to corporations and the general public," explained Seungmin Kim, CEO/CTO of SM Systems Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.